Thermo Fisher Scientific
Market Cap
US$204.0b
Last Updated
2021/01/23 23:13 UTC
Data Sources
Company Financials +
Executive Summary
Thermo Fisher Scientific Inc. provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. More Details
Snowflake Analysis
Solid track record with mediocre balance sheet.
Similar Companies
Share Price & News
How has Thermo Fisher Scientific's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TMO is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: TMO's weekly volatility (5%) has been stable over the past year.
Market Performance
7 Day Return
2.3%
TMO
2.9%
US Life Sciences
2.3%
US Market
1 Year Return
54.2%
TMO
51.3%
US Life Sciences
23.8%
US Market
Return vs Industry: TMO exceeded the US Life Sciences industry which returned 51.2% over the past year.
Return vs Market: TMO exceeded the US Market which returned 23.7% over the past year.
Shareholder returns
| TMO | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.3% | 2.9% | 2.3% |
| 30 Day | 12.3% | 11.0% | 4.8% |
| 90 Day | 7.2% | 17.2% | 14.5% |
| 1 Year | 54.6%54.2% | 51.6%51.3% | 26.6%23.8% |
| 3 Year | 136.0%134.1% | 110.3%109.0% | 45.0%35.4% |
| 5 Year | 295.8%289.7% | 249.6%245.2% | 126.2%101.0% |
Long-Term Price Volatility Vs. Market
How volatile is Thermo Fisher Scientific's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall St
Should You Be Adding Thermo Fisher Scientific (NYSE:TMO) To Your Watchlist Today?2 weeks ago | Simply Wall St
Is Thermo Fisher Scientific Inc.'s (NYSE:TMO) Latest Stock Performance Being Led By Its Strong Fundamentals?1 month ago | Simply Wall St
How Does Thermo Fisher Scientific's (NYSE:TMO) CEO Salary Compare to Peers?Valuation
Is Thermo Fisher Scientific undervalued compared to its fair value and its price relative to the market?
41.87x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: TMO ($514.6) is trading above our estimate of fair value ($391.56)
Significantly Below Fair Value: TMO is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: TMO is good value based on its PE Ratio (41.9x) compared to the US Life Sciences industry average (48.5x).
PE vs Market: TMO is poor value based on its PE Ratio (41.9x) compared to the US market (21.3x).
Price to Earnings Growth Ratio
PEG Ratio: TMO is poor value based on its PEG Ratio (4.3x)
Price to Book Ratio
PB vs Industry: TMO is good value based on its PB Ratio (6.4x) compared to the US Life Sciences industry average (8.7x).
Next Steps
Future Growth
How is Thermo Fisher Scientific forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?
9.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TMO's forecast earnings growth (9.6% per year) is above the savings rate (2%).
Earnings vs Market: TMO's earnings (9.6% per year) are forecast to grow slower than the US market (21.6% per year).
High Growth Earnings: TMO's earnings are forecast to grow, but not significantly.
Revenue vs Market: TMO's revenue (4.4% per year) is forecast to grow slower than the US market (10.6% per year).
High Growth Revenue: TMO's revenue (4.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TMO's Return on Equity is forecast to be high in 3 years time (21.3%)
Next Steps
Past Performance
How has Thermo Fisher Scientific performed over the past 5 years?
17.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TMO has high quality earnings.
Growing Profit Margin: TMO's current net profit margins (17.1%) are higher than last year (14.2%).
Past Earnings Growth Analysis
Earnings Trend: TMO's earnings have grown by 17.8% per year over the past 5 years.
Accelerating Growth: TMO's earnings growth over the past year (35.9%) exceeds its 5-year average (17.8% per year).
Earnings vs Industry: TMO earnings growth over the past year (35.9%) exceeded the Life Sciences industry 30.4%.
Return on Equity
High ROE: TMO's Return on Equity (15.3%) is considered low.
Next Steps
Financial Health
How is Thermo Fisher Scientific's financial position?
Financial Position Analysis
Short Term Liabilities: TMO's short term assets ($18.2B) exceed its short term liabilities ($6.2B).
Long Term Liabilities: TMO's short term assets ($18.2B) do not cover its long term liabilities ($26.0B).
Debt to Equity History and Analysis
Debt Level: TMO's debt to equity ratio (64%) is considered high.
Reducing Debt: TMO's debt to equity ratio has increased from 63.8% to 64% over the past 5 years.
Debt Coverage: TMO's debt is well covered by operating cash flow (33.7%).
Interest Coverage: TMO's interest payments on its debt are well covered by EBIT (12.1x coverage).
Balance Sheet
Next Steps
Dividend
What is Thermo Fisher Scientific current dividend yield, its reliability and sustainability?
0.17%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: TMO's dividend (0.17%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.38%).
High Dividend: TMO's dividend (0.17%) is low compared to the top 25% of dividend payers in the US market (3.85%).
Stability and Growth of Payments
Stable Dividend: TMO is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: TMO is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: TMO is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TMO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.4yrs
Average management tenure
CEO
Marc Casper (52 yo)
11.25yrs
Tenure
US$19,023,145
Compensation
Mr. Marc N. Casper has been the Chief Executive Officer and President of Thermo Fisher Scientific, Inc. since October 15, 2009 and also has been its Chairman of the Board of Directors since February 26, 20...
CEO Compensation Analysis
Compensation vs Market: Marc's total compensation ($USD19.02M) is above average for companies of similar size in the US market ($USD10.57M).
Compensation vs Earnings: Marc's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 11.25yrs | US$19.02m | 0.076% $ 154.6m | |
| Senior VP & CFO | 5.42yrs | US$5.20m | 0.0090% $ 18.4m | |
| Executive VP & COO | 3.42yrs | US$9.41m | 0.036% $ 74.2m | |
| Senior VP & Retiring President of Customer Channels | no data | US$4.33m | 0.0030% $ 6.2m | |
| Senior VP & President of Regions | 10yrs | US$3.97m | 0.0038% $ 7.8m | |
| Executive Vice President | 3.42yrs | US$6.01m | 0.0043% $ 8.8m | |
| VP & Chief Accounting Officer | 20yrs | no data | 0.0045% $ 9.2m | |
| Senior VP & Chief Information Officer | 1.5yrs | no data | no data | |
| Vice President of Investor Relations | 14.17yrs | no data | no data | |
| Senior VP & General Counsel | 3yrs | no data | 0.0016% $ 3.3m | |
| VP & Chief Communications Officer | 0.25yr | no data | no data | |
| Senior Vice President of Strategy & Corporate Development | 0.75yr | no data | no data |
3.4yrs
Average Tenure
56yo
Average Age
Experienced Management: TMO's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 11.25yrs | US$19.02m | 0.076% $ 154.6m | |
| Independent Director | 14.17yrs | US$347.33k | 0.019% $ 38.4m | |
| Independent Director | 12.67yrs | US$351.18k | 0.0047% $ 9.6m | |
| Lead Independent Director | 0.92yr | US$350.62k | 0.0038% $ 7.8m | |
| Independent Director | 20.67yrs | US$505.62k | 0.0044% $ 8.9m | |
| Independent Director | 10.08yrs | US$360.62k | 0.0032% $ 6.5m | |
| Independent Director | 4.67yrs | US$335.62k | 0.0022% $ 4.4m | |
| Director & Member of Scientific Advisory Board | 11.67yrs | US$350.62k | 0.0017% $ 3.5m | |
| Member of Scientific Advisory Board | 8.83yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.83yrs | US$321.77k | 0.00079% $ 1.6m |
9.5yrs
Average Tenure
62yo
Average Age
Experienced Board: TMO's board of directors are considered experienced (9.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TMO insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Thermo Fisher Scientific Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Thermo Fisher Scientific Inc.
- Ticker: TMO
- Exchange: NYSE
- Founded: 1956
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$203.954b
- Shares outstanding: 396.34m
- Website: https://www.thermofisher.com
Number of Employees
Location
- Thermo Fisher Scientific Inc.
- 168 Third Avenue
- Waltham
- Massachusetts
- 2451
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| TMO | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Jan 1980 |
| TN8 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jan 1980 |
| TN8 | XTRA (XETRA Trading Platform) | Yes | Common Stock | DE | EUR | Jan 1980 |
| TMO * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Jan 1980 |
| TFS | SWX (SIX Swiss Exchange) | Yes | Common Stock | CH | CHF | Jan 1980 |
| 0R0H | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jan 1980 |
| TN8 | ETLX (Eurotlx) | Yes | Common Stock | IT | EUR | Jan 1980 |
| TMOF | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Jan 1980 |
| TMO | BVL (Bolsa de Valores de Lima) | Yes | Common Stock | PE | USD | Jan 1980 |
| TMOS34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH 48 REP 1 COM | BR | BRL | Apr 2016 | |
| TMO | BASE (Buenos Aires Stock Exchange) | CEDEAR EACH 22 REP 1 | AR | ARS | Apr 2019 |
Biography
Thermo Fisher Scientific Inc. provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. The company’...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/23 23:13 |
| End of Day Share Price | 2021/01/22 00:00 |
| Earnings | 2020/09/26 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.